Transforming Small Cell Lung Cancer Management With DLL3-Targeted Therapies

Stream Link 8 PM ET: https://globalmeet.webcasts.com/starthere.jsp?ei=1692462&tp_key=56fa3ac274

Program Description

While small cell lung cancer (SCLC) accounts for only 14% of all lung cancer cases, it is typically aggressive and difficult to treat. The quick development of resistance to chemotherapy combined with limited second-line treatment options presents significant challenges for patients with SCLC and complicates medication management. This program will examine the role of delta-like ligand 3 (DLL3)-targeted therapies including their mechanisms of action, efficacy data, and adverse effect profiles. Oncology pharmacists must be informed about these investigational and emerging treatment regimens as well as updated guideline recommendations to support appropriate and effective treatment protocols for SCLC. This webinar will present oncology pharmacists with actionable strategies to not only prepare for additional second-line treatment options in SCLC but also address medication-related toxicities to facilitate comprehensive patient care.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: November 13, 2024
Expiration date: January 13, 2025

Time to complete activity: 1.0 hour

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the mechanisms of action and safety profiles of new and emerging DLL3-targeted therapies for small cell lung cancer (SCLC).
• Describe emerging strategies to utilize DLL3-targeted therapies in the treatment of SCLC and how recent trial evidence may inform evolving treatment paradigms.
• Illustrate approaches to identify, prevent, and manage treatment-associated adverse effects of DLL3-targeted therapies.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-268-L01-P. The activity is available for CE credit through January 13, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Amanda S. Cass, PharmD, BCPS, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: G1 Therapeutics, Takeda, Regeneron, Daiichi Sankyo

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Daphne Davis, PharmD, BCOP; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.


Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms